The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 797-801

  Ma, Qiong ^a   Zhou, Yong ^a   Ma, Baoan ^a   Chen, Xiang ^a   Wen, Yanhua ^a   Liu, Yunyan ^a   Fan, Qingyu ^a   Qiu, Xiuchun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD44; CXCR4; HER2; Osteosarcoma

Indexed keywords

CD44V ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PILOT STUDY; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 84863124438     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.558     Document Type: Article

References (21)

1. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ and Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 425: 307-311, 2003.
2. Liekens S, Schols D and Hatse S: CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16: 3903-3920, 2010.
3. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P and Serra M: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewings sarcoma. Eur J Cancer 41: 1349-1361, 2005.
4. Foster H, Knox S, Ganti AK, et al: HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. Am J Clin Oncol 26: 188-191, 2003.
5. Sato T, Peiper M, Heinecke A, et al: Expression of HER2/neu does not correlate with survival in soft tissue sarcoma. Oncologie 26: 268-271, 2003.
6. Thomas DG, Giordano TJ, Sanders D, et al: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewings sarcoma. Clin Cancer Res 8: 788-893, 2002.
7. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al: Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40: 963-970, 2004.
8. Akatsuka T, Wada T, Kokai Y, et al: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94: 1397-1404, 2002.
9. Cichy J and Puré E: The liberation of CD44. J Cell Biol 161: 839-843, 2003.
10. Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: a review. Sarcoma: 13 April, 2011 (E-pub ahead of print).
11. PosthumaDeBoer J, Witlox MA, Kaspers GJ and van Royen BJ: Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 28: 493-503, 2011.
12. Savage SA and Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma: 8 March, 2011 (E-pub ahead of print).
13. Kilpatrick SE, Geisinger KR, King TS, et al: Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14: 1277-1283, 2011.
14. Akatsuka T, Wada T, Kokai Y, et al: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94: 1397-1404, 2002.
15. Maitra A, Wanzer D, Weinberg AG, et al: Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcoma. Cancer 92: 677-683, 2001.
16. Zhou H, Randall RL, Brothman AR, et al: Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25: 27-32, 2003.
17. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al: Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40: 963-970, 2004.
18. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L and Amadori D: The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology 80: 225-231, 2011.
19. Liekens S, Schols D and Hatse S: CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16: 3903-3920, 2010.
20. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 30: 269-270, 2011.
21. Takahashi K, Stamenkovic I, Cutler M, Saya H and Tanabe KK: CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 11: 2223-2232, 1995.